Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

US11180478B2 · kind B2 · utility

Assignee

• BETA PHARMA, INC. · US

Inventors

• Michael N. Greco · Lansdale, US
• Michael John Costanzo · Bonney Lake, US
• Michael Alan Green · Easton, US
• Jirong Peng · Mequon, US
• Victoria Lynn Wilde · Montclair, US
• Don Zhang · Princeton, US

Key dates

• Filing date: Jun 15, 2018
• Grant date: Nov 23, 2021
• Expiry date: Jun 15, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.